RePORT International Resources

The MARM-TB-Drug-Regimens dataset contains the FDG PET/CT scans from common marmosets infected with Mycobacterium tuberculosis (MTB) H37Rv and imaged with FDG (Fluorodeoxyglucose) during experiments to characterize the action of various drugs and regimens used against the infection. Baseline CT scans were collected before aerosol exposure to MTB and disease was allowed to develop for 6 to 7 weeks until frank lung disease was evident. PET/CT scans were collected at about 5 weeks post infection and immediately before the start of treatment and every two weeks thereafter until eight weeks of treatment. The data is zipped into files by drug treatment with typically 5 animals per group and 5 scans per animal so that the drug groups of interest can be downloaded. The drugs administered include bedaquiline, delamanid, isoniazid, linezolid, moxifloxacin, pretomanid, pyrazinamide, quabodepistat, and rifampicin along with combinations of these. The study dates were Feb 2016-Feb 2026.

The NIAID ChemDB, or the National Institute of Allergy and Infectious Diseases ChemDB HIV, Opportunistic Infection and Tuberculosis Therapeutics Database, is a compendium of small molecules that have been tested for preclinical activity against HIV and opportunistic pathogens.

The NIAID Data Ecosystem Discovery Portal is a centralized search hub for infectious and immune-mediated disease datasets and computational tools from over 70 sources. These include NIAID-funded repositories as well as globally-relevant infectious and immune-mediated disease (IID) repositories from NIH and beyond. Resources in the Discovery Portal include -omics data, clinical data, epidemiological data, pathogen-host interaction data, flow cytometry, imaging, workflows, computational tools, and more. The NIAID Data Ecosystem Discovery Portal does not store data. Instead, it contains harmonized and detailed information (metadata) about datasets, computational tools, and resources. Users can then navigate to datasets, tools, and resources through external links.

The NIAID Stats Calculator application is provided by the Bioinformatics and Computational Biology Branch to allow users to perform quick sanity checks when exploring experimental results data. Please refer to the website for the details.

The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Version 2.1 used in … clinical trials for safety data reporting to maintain accuracy and consistency in the evaluations of SAEs.

This document provides a detailed list of essential documents” (regulatory documents). “The purpose and/or description of these documents is/are given with a recommended location where they should be filed during the conduct of a clinical trial.

NIH NIAID - Grants and Fundings - Searchable Database

Advancing TB research through open-access, multi-domain, global TB data and tools.

Background: Conversational chatbots are increasingly integrated into daily life, including in health-related information-seeking, decision support, social interaction, and informal caregiving contexts. These systems are now used by individuals to interpret symptoms, manage chronic conditions, make financial and health decisions, and mitigate social isolation, often without professional oversight. Use of chatbot technologies is expanding rapidly, and patterns of adoption, benefit, and risk are likely to differ across populations, contexts, and system designs. At present, there is insufficient evidence regarding the benefits and harms of chatbot use for health and well-being or to characterize unintended consequences such as misinformation, over-reliance, altered decision-making, or delayed engagement with professional care. Rigorous research is needed to understand how chatbot design (including potential built-in safeguards), chatbot use (including but not limited to context and frequency of use), and user characteristics interact to shape health-relevant outcomes. Efforts should inform safeguards, standards, and evidence-based guidance. Purpose: This topic encourages multidisciplinary research that identifies, measures, and explains the benefits and harms associated with chatbot use (both chatbot-based interventions or treatments and routine chatbot use) across a variety of populations, use cases, and settings. Of interest are studies that move beyond proof-of-concept to characterize mechanisms, safety, and impacts on behavior, decision-making, and health outcomes. Of particular interest are studies that: - Identify risk mechanisms: including automation bias, persuasive effects, misinformation exposure, behavioral dependency, and substitution for professional care, and document adverse outcomes across different chatbot designs, and health or wellbeing-related purposes. - Compare safety and performance across chatbot models, including adaptive versus static designs and varying degrees of personalization, information retrieval, or relational engagement. - Examine impacts on decision-making and autonomy: including how chatbot use influences judgment, independence, help-seeking behavior, and relationships with family, caregivers, and clinicians. - Characterize health and functional outcomes associated with patterns of use: including frequency, duration, and longitudinal engagement, with attention to cognitive, emotional, social, and behavioral consequences. - Develop and test safeguards: including monitoring strategies and design features that promote safe, ethical, secure, and beneficial use, particularly for populations at elevated risk of harm. - Ideally, studies will focus on advancing understanding of causal mechanisms driving observed or hypothesized effects and emphasize methodological rigor, appropriate comparators, and real-world relevance.

The NIH Extramural Nexus is the NIH's official platform for updates on grants policies, application processes, and funding news. Hosted within the NIH Grants & Funding website, it serves as a centralized resource for researchers, administrators, and institutions navigating the NIH extramural research landscape. The platform offers timely information on policy changes, application tips, and new resources, ensuring the research community stays informed and compliant with NIH requirements.

Learn the basics with NIH Grants Process: A Walk-Through for Beginners Tune in for answers to your questions in the NIH Expert Q&A Panel: Part 1 Test your knowledge with Submission Policies: You Make the Call More questions and answers in the NIH Expert Q&A Panel: Part 2 Take our panelists’ advice: Grant Application Tips from NIH Experts

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Notice of Funding Opportunity Announcement requires that at lease 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Fogarty's new webpage 'NIH Support of International Research: Navigating NIH Public Resources' website page contains useful information for researchers. Alongside links to NIH Guide Notices and NIH extramural news resources, the page offers guidance on the newly published application and award structure for applications that request funding for international organizations (the PA-26-002 NIH Collaborative International Research Project--Parent PF5 Clinical Trial Optional).

Funding Opportunity Purpose: The purpose of this notice of funding opportunity (NOFO) is to support innovative basic, clinical, translational, and implementation science research relevant to HIV and substance use. This initiative encourages high risk high impact transformative studies that advance knowledge and strategies for HIV prevention, diagnosis, treatment and virus suppression in people who use substances and/or have a substance use disorder. Funding Opportunity Goal(s): To support basic, clinical, translational, and implementation research in the field of substance use. To develop new knowledge and approaches for the prevention, diagnosis, and treatment of drug use, misuse, and addiction, drug overdose, and related health outcome, including HIV/AIDS. Application due date: Multiple dates, see announcement.

Most important training for any investigator would be HSP/GCP where they need to learn and understand how Ethical conduct of research is done and why it is important. I have pasted various links below that cover all the topics extensively. DAIDS learning portal, HANC network , DAIDS score manual have good training modules .

This document provides a detailed list of source documentation requirements during the conduct of a clinical trial. Source documentation refers to the record of the participant before, during and after a trial.

Application due date: Multiple dates, see announcement

Application due date: Multiple dates, see announcement

The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote the dissemination and implementation of evidence-based interventions among relevant communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters remain relevant. All applications must be within the scope of the mission of one of the Institutes/Centers listed in the notice. Application DEADLINE: Multiple dates, see announcement.

Application due date: Multiple dates, see announcement